| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014282 |
| Receipt No. | R000016626 |
| Official scientific title of the study | What is the best biomarker to predict acute kidney injury during living donor renal transplantation, a single center experience. |
| Date of disclosure of the study information | 2014/06/16 |
| Last modified on | 2017/04/26 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | What is the best biomarker to predict acute kidney injury during living donor renal transplantation, a single center experience. | |
| Title of the study (Brief title) | The best biomarker during renal transplantation. | |
| Region |
|
|
| Condition | |||
| Condition | living donor renal transplantation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The investigation of the biomarker to predict renal ischemic reperfusion injury during living donor renal transplantation. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The concentrations of biomarkers during living donor renal transplantation . The measured biomarkers were included urinary L-FABP(liver-type fatty acid binding protein), urinary H-FABP(heart-type fatty acid binding protein), urinary NGAL(neutrophil gelatinase-associated lipocalin), urinary Lf(lactoferrin) and plasma IL-18(interleukin 18). |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with written informed consent(or by next of kin) | |||
| Key exclusion criteria | Patients without written informed consent(or by next of kin) | |||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Rikizo Kogawa |
| Organization | Toho University School of Medicine |
| Division name | Department of Anesthesiology |
| Address | 6-11-1 , Omori-Nishi Ota-ku , Tokyo 143-8541 , Japan |
| TEL | 03-3762-4151 |
| rikizo.kogawa@med.toho-u.ac.jp | |
| Public contact | |
| Name of contact person | Rikizo Kogawa |
| Organization | Toho University School of Medicine |
| Division name | Department of Anesthesiology |
| Address | 6-11-1 , Omori-Nishi Ota-ku , Tokyo 143-8541 , Japan |
| TEL | 03-3762-4151 |
| Homepage URL | |
| rikizo.kogawa@med.toho-u.ac.jp | |
| Sponsor | |
| Institute | Toho University School of Medicine , Department of Anesthesiology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東邦大学医療センター大森病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | We measured the concentrations of biomarkers during living donor renal transplantation. The biomarkers were urinary L-FABP(liver-type fatty acid binding protein), urinary H-FABP(heart-type fatty acid binding protein), urinary NGAL(neutrophil gelatinase-associated lipocalin), urinary Lf(lactoferrin) and plasma IL-18(interleukin 18). The urine and blood samples were collected at preoperative period, postoperative period from the donor and the initial urine after the anastomosis, 5hours after the reperfusion, 24hours after the reperfusion, and the week after the surgery from the recipient. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016626 |